⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

January 1, 1990Journal of Cardiovascular Pharmacology

Effects of Captopril on Atherosclerosis in Cynomolgus Monkeys

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does oral captopril reduce the progression of atherosclerosis in cholesterol-fed cynomolgus monkeys?

Population

24 cynomolgus monkeys fed a high cholesterol diet (or normal diet for control)

Comparison

Oral captopril 25 mg/kg or 50 mg/kg twice daily… vs Placebo medication with high cholesterol diet

Design

Preclinical

Follow-up

6 months

Authors

GÅGunnar ÅbergBridge Pharma (United States)PFPatricia FerrerUnifor

Discussion

Loading...

Member takes

Implication

Provides preclinical support for lipid-independent ACE inhibition in primates; leaves open translation to human atherosclerosis prevention.

Key Points

To determine whether oral administration of the ACE inhibitor captopril reduces the development and progression of diet-induced atherosclerosis in cynomolgus monkeys.
Assigned 24 cynomolgus monkeys (N=24) across four groups for 6 months: normal diet with placebo, high-cholesterol diet with placebo, high-cholesterol diet with low-dose captopril (25 mg/kg twice daily), and high-cholesterol diet with high-dose captopril (50 mg/kg twice daily).
Monitored total serum cholesterol, HDL, and triglyceride levels throughout the study and evaluated vascular pathology at 6 months via gross pathology, histopathology, and biochemical assays.
Captopril administration did not alter total serum cholesterol, HDL, triglyceride levels, or the total cholesterol/HDL ratio.
Captopril significantly reduced the progression of arterial lesions compared to untreated high-cholesterol controls, rendering the coronary arteries of treated animals practically free from atherosclerotic plaque.

Structured PICO

Does oral captopril reduce the progression of atherosclerosis in cholesterol-fed cynomolgus monkeys?

P

Population

24 cynomolgus monkeys fed a high cholesterol diet (or normal diet for control)

I

Intervention

Oral captopril 25 mg/kg or 50 mg/kg twice daily for 6 months

C

Comparator

Placebo medication with high cholesterol diet (and a separate control group with normal diet and placebo)

O

Outcome

Progression of atherosclerosis assessed by gross pathology, histopathology, and biochemical methodssurrogate

Captopril significantly reduces the progression of atherosclerosis in cholesterol-fed monkeys independent of lipid levels.

Cite This Study

Åberg et al. (1990) studied this question.

synapsesocial.com/papers/6a75daf01078cf7de2b2453a https://doi.org/10.1097/00005344-199000155-00010

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Effects of Captopril on Atherosclerosis in Cynomolgus Monkeys1990 · 185 citations
2Anti‐atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high‐cholesterol diet1999 · 82 citations
3Antiatherosclerotic and Antioxidative Effects of Captopril in Apolipoprotein E-Deficient Mice1998 · 108 citations
4Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit.1990 · 414 citations
5Impact of captopril on cardiac mitochondrial function in an in-vivo animal model of atherosclerosis2006